In January 2018, ASLAN announced that it had fully acquired the global commercial rights to varlitinib from its partner, Array BioPharma. Previously, the agreement stipulated that ASLAN develop the drug and sublicense it, and we view the current agreement as a significant improvement. We believe that ASLAN brings significant value to the table in Asian development capacity. The licence is now consistent with the goal of directly commercialising varlitinib in the US and parts of Asia.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs